

Special Issue

Innovative Strategies for the Diagnosis and Treatment of Sarcopenia and Osteoporosis

Message from the Guest Editors

Sarcopenia and osteoporosis are prevalent age-related musculoskeletal disorders that contribute significantly to frailty, falls, fractures, and reduced quality of life in older adults. With the global aging population on the rise, there is a growing need for innovative diagnostic tools, preventive strategies, and effective treatment modalities. This Special Issue aims to highlight recent advances in the understanding and management of sarcopenia and osteoporosis. We invite original research articles, clinical studies, and comprehensive reviews focusing on pharmacological treatments, biomarker development, and novel regenerative and technological approaches. The goal is to foster interdisciplinary collaboration and promote integrative solutions for improving musculoskeletal health in aging populations.

Guest Editors

Dr. Wei-Bin Hsu

Sports Medicine Center, Chang Gung Memorial Hospital, No. 6, West Section, Chia-Pu Road, Chia-Yi County, Pu-Tz City 61363, Taiwan

Dr. Meng-Huang Wu

1. Department of Orthopaedics, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan
2. Department of Orthopedics, Taipei Medical University Hospital, Taipei 11031, Taiwan
3. TMU Biodesign Center, Taipei Medical University, Taipei 11031, Taiwan

Deadline for manuscript submissions

28 February 2026



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/244883

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).